Seer Announces Closing of Public Offering of Common Stock
Seer, a life sciences company, announced the closing of a public offering of 3,750,000 shares of Class A common stock at $67.00 per share, generating $251.25 million before commissions. In this offering, Seer sold 1,650,000 shares while 2,100,000 shares were sold by existing stockholders. The offering was managed by J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. The SEC approved the offering on January 27, 2021. The funds raised will be used to enhance Seer's proteomics platform, including the Proteograph Product Suite.
- The offering raised $251.25 million, which can be used for expanding the Proteograph Product Suite.
- The offering allows Seer to strengthen its financial position for future growth.
- Potential dilution of shares for existing shareholders due to the public offering.
REDWOOD CITY, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten public offering of 3,750,000 shares of Class A common stock at a public offering price of
J.P. Morgan, Morgan Stanley, BofA Securities and Cowen acted as lead book-running managers for the offering.
Registration statements relating to the shares being sold in this offering were declared effective by the Securities and Exchange Commission on January 27, 2021. The offering was made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone: +1 (866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; and Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (833) 297-2926, or by emailing PostSaleManualRequests@broadridge.com. Copies of the final prospectus related to the offering are available at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Seer
Seer is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph Product Suite, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures.
Investor Contact
Carrie Mendivil
investor@seer.bio
FAQ
What was the share price for Seer's recent offering?
How many shares did Seer sell in its public offering?
Who managed the public offering for Seer?
What will Seer use the funds from the offering for?
